BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC 50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease In Vitro BMS-582949 displays a p38α IC 50 of 13 nM and a cellular TNFα IC 50 of 50 nM. BMS-582949 is a weak inhibitor of CYP3A4 BMS-582949 displays >2000-fold selectivity for p38α over a diverse panel of 57 kinases that include serine kinases, nonreceptor tyrosine kinases, receptor tyrosine kinases, and the p38γ and δ isoforms. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BMS-582949 (5-100 mg/kg, orally) is effective in both the acute murine model of inflammation and rat adjuvant arthritis model despite its slightly reduced potency . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (250-300 g) adjuvant arthritis model . Dosage: 1, 10, 100 mg/kg. Administration: Orally once daily (from day 11 to day 19). Result: Displayed dose-dependent reduction in paw swelling with qd dosing, with efficacy observed at doses of 10 and 100 mg/kg. Form:Solid IC50& Target:p38α MAPK 13 nM (IC 50 ) TNFα 50 nM (IC 50 , in cells)